These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6684127)

  • 21. Binding of methyltrienolone to androgen receptors in human skin fibroblasts is enhanced by insulin.
    Chang YT; Ghirri P; Migeon CJ; Brown TR
    J Androl; 1992; 13(3):242-8. PubMed ID: 1601743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between genotype, phenotype and sex of rearing in 111 patients with partial androgen insensitivity syndrome.
    Deeb A; Mason C; Lee YS; Hughes IA
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):56-62. PubMed ID: 15963062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steroid receptor forms and their interaction with cytoplasmic modulators.
    Sato B; Nishizawa Y; Maeda Y; Noma K; Honma T; Matsumoto K
    J Steroid Biochem; 1983 Jul; 19(1A):315-21. PubMed ID: 6887866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Male pseudohermaphroditism: diagnosis in cell culture.
    Pinsky L; Kaufman M; Lambert B; Faucher G; Rosenfeld R
    Can Med Assoc J; 1977 Jun; 116(11):1274-5, 1277. PubMed ID: 861885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Congenital androgen insensitivity due to a qualitatively abnormal androgen receptor.
    Pinsky L; Kaufman M; Summitt RL
    Am J Med Genet; 1981; 10(1):91-9. PubMed ID: 7294064
    [No Abstract]   [Full Text] [Related]  

  • 26. Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction.
    Quigley CA; Tan JA; He B; Zhou ZX; Mebarki F; Morel Y; Forest MG; Chatelain P; Ritzén EM; French FS; Wilson EM
    Mech Ageing Dev; 2004; 125(10-11):683-95. PubMed ID: 15541764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the molecular consequences of different mutations at residue 754 and 690 of the androgen receptor (AR) and androgen insensitivity syndrome (AIS) phenotype.
    Tadokoro R; Bunch T; Schwabe JW; Hughes IA; Murphy JC
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):253-60. PubMed ID: 19178528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical and molecular spectrum of androgen insensitivity syndromes.
    Hiort O; Sinnecker GH; Holterhus PM; Nitsche EM; Kruse K
    Am J Med Genet; 1996 May; 63(1):218-22. PubMed ID: 8723113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of male pseudohermaphroditism with normal androgen receptor binding and 47,XYY karyotype.
    Bosch-Banyeras JM; Audi L; Sarret E; Bau A; Bosch-Marcet J; Bernet M; Iriondo L; Cuatrecasas JM
    Ann Genet; 1985; 28(2):125-9. PubMed ID: 3876063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A naturally occurring mutation in the human androgen receptor of a subject with complete androgen insensitivity confers binding and transactivation by estradiol.
    Bonagura TW; Deng M; Brown TR
    Mol Cell Endocrinol; 2007 Jan; 263(1-2):79-89. PubMed ID: 17011702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered mRNA expression due to insertion or substitution of thymine at position +3 of two splice-donor sites in the androgen receptor gene.
    Trifiro MA; Lumbroso R; Beitel LK; Vasiliou DM; Bouchard J; Deal C; Van Vliet G; Pinsky L
    Eur J Hum Genet; 1997; 5(1):50-8. PubMed ID: 9156321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel androgen receptor gene mutations in Australian patients with complete androgen insensitivity syndrome.
    MacLean HE; Ball EM; Rekaris G; Warne GL; Zajac JD
    Hum Mutat; 2004 Mar; 23(3):287. PubMed ID: 14974091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen binding in cultured human fibroblasts from patients with idiopathic hypospadias.
    Schweikert HU; Knauf W; Romalo G; Höller W; Bidlingmaier F; Knorr D
    Horm Metab Res; 1987 Oct; 19(10):497-501. PubMed ID: 3501393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlations between fibroblast androgen receptor levels and clinical features in abnormal male sexual differentiation and infertility.
    Warne GL; Gyorki S; Risbridger GP; Khalid BA; Funder JW
    Aust N Z J Med; 1983 Aug; 13(4):335-41. PubMed ID: 6580856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial androgen insensitivity as a cause of genital maldevelopment.
    Pereira RR; Brinkmann AO; Ring D; Hodgins MB
    Helv Paediatr Acta; 1984 Aug; 39(3):255-9. PubMed ID: 6544308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen insensitivity syndrome: gonadal androgen receptor activity.
    Coulam CB; Graham ML; Spelsberg TC
    Am J Obstet Gynecol; 1984 Nov; 150(5 Pt 1):531-3. PubMed ID: 6333820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intracellular and extracellular proteins binding androgenic hormones. Biochemical properties and clinical significance].
    Molinatti GM; Biffignandi P; Massucchetti C
    Minerva Med; 1983 Mar; 74(11):505-23. PubMed ID: 6339992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defective activation of androgen-receptor complexes: a marker of androgen insensitivity.
    Kaufman M; Pinsky L; Simard L; Wong SC
    Mol Cell Endocrinol; 1982 Feb; 25(2):151-62. PubMed ID: 7056433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defective androgen action at the cellular level in the androgen resistance syndromes. I. Differences between the complete and incomplete testicular feminization syndromes.
    Medina M; Chávez B; Pérez-Palacios G
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1243-6. PubMed ID: 7298803
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.